Abstract 4128
Background
E-health incorporates a range of standards, tools and activities that use electronic to deliver information, resources and services in relation to health care. Final goal is improve quality of health information, strengthening national health systems and ensuring accessible health for population with reduce costs.
Imuno-oncology uses the power of the body’s own immune system to prevent, target, control, and eliminate cancer. Most of Immune related Adverse Events are moderate, reversible if detected early and properly. Teleoncology can decrease the existing gaps between care provider and patients. Allow patients to contact with professionals, permit communication, emotional support, regular assessment and, patient empowerment during and after treatment which rise patient adherence.
Methods
Describe the use of e-health systems to promote cancer care. How e-health technology can improve cancer nurse practise and empower cancer patients receiving Immunotherapy? 3 phases: first literature review searching for e-health nurses interventions with cancer patients in last years. Second; to recruit nurses’ priorities in the 2 countries (Portugal, Spain) to assess and control adherence. Finally a multimodal pathway using e-health technology to provide a checklist for professionals will be develop.
Results
The intended results are to provide a standardized system in order to facilitate the use of e-health, for cancer patients and professionals. Display evidence-based models using a process for framing a question, locating, assessing, evaluating, and repeating it as needed. Is projected to recognize professionals needed skills to improve e-Health technologies to support cancer care, specify e-health interventions for the management of immunotherapy side effects and factors that users perceive or experience as facilitators or barriers to the uptake and implementation of eHealth technologies.
Conclusions
Technology-based interventions could be suitable for immunotherapy treatment. The study will recognize the necessary skills and e-health best system to improve nursing care, adherence and promote quality of life. Further research is required to fully assess the impact of technology as an information and support mechanism for carers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract